Lanean...
Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
BACKGROUND: Treatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited. In a phase III trial, eribulin demonstrated a significant improvement in overall survival compared to treatment of physician’s choice, but had limited tolerability because of neutro...
Gorde:
| Argitaratua izan da: | Breast Cancer Res Treat |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer US
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8233258/ https://ncbi.nlm.nih.gov/pubmed/33797651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-021-06175-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|